Alphapharm Revenue and Competitors

Claim your profile

Dawes Point, AU

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Alphapharm's estimated annual revenue is currently $46.2M per year.(i)
  • Alphapharm's estimated revenue per employee is $201,000

Employee Data

  • Alphapharm has 230 Employees.(i)
  • Alphapharm grew their employee count by -3% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$24.1M120-1%N/AN/A
#2
$45.6M227N/AN/AN/A
#3
$11.3M56-26%N/AN/A
#4
$60.1M299-1%N/AN/A
#5
$46.2M230-3%N/AN/A
#6
$26.3M131-8%N/AN/A
#7
$60.1M299-2%N/AN/A
#8
$238.4M118611%N/AN/A
#9
$262.7M1307-16%N/AN/A
#10
$2403.6M11958N/AN/AN/A

Generic Medicines, OTC pharamceuticals, Pharmaceuticals Alphapharm has been developing and making generic medicines in Australia for almost 30 years. Millions of Australians take an Alphapharm generic medicine every day. In fact, we’ve become the largest supplier of medicines to the government subsidised Pharmaceutical Benefits Scheme and Australia’s leader in generic medicines. Alphapharm medicines are available Australia-wide. Alphapharm medicines are made to the highest global quality standards and exported to more than 50 countries, including those in Europe and the US. Globally, Alphapharm is part of Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest — and highest quality — product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third-largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies.

keywords:N/A

N/A

Total Funding

230

Number of Employees

$46.2M

Revenue (est)

-3%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$55.9M2316%N/A
#2
$73.7M2315%N/A
#3
$68.9M232-1%N/A
#4
$53.8M233N/AN/A
#5
N/A2466%N/A